Please enter the email address you used to register, then we will send you a link to choose a new password
Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and lowers the price ...
Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Man...
Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and maintains $36 pr...
ABEO: -55% | Abeona Therapeutics shares are trading lower after the company announced the FDA issued a Complete Response Letter...
Receives FDA Complete Response Letter (CRL) based on need for additional CMC information CRL did not identify deficiencies rela...